Translating Innovation to Clinic: End-to-End Bioprocess Development and cGMP Manufacturing of N332-GT5 HIV Vaccine Candidate for First-in-Human Trials HVTN144

Abstract excerpt

The successful translation of rationally designed HIV-1 immunogens into effective vaccines requires manufacturing platforms that maintain structural conformity while meeting clinical-grade quality standards. We developed and scaled a robust, cGMP-compliant process for N332-GT5 gp140, a germline-targeting envelope trimer designed to initiate broadly neutralizing antibody responses, which is now undergoing first-in-...

Topics

Open a Topic to create a Post that cites this publication.

• Amino Acid Sequence
• Antibodies, Monoclonal
• CAR-T cell therapy research
• CRISPR and Genetic Engineering
• HIV Research and Treatment
• Monoclonal and Polyclonal Antibodies Research
• vaccines and immunoinformatics approaches
• Viral Infectious Diseases and Gene Expression in Insects

Identifiers and source

Literature Corpus work

f2bbee61-8f21-5a60-ba88-940f0e3ffea6

DOI

10.64898/2026.06.11.731363